Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Current Liabilities (2019 - 2025)

C4 Therapeutics' Total Current Liabilities history spans 7 years, with the latest figure at $33.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 26.88% year-over-year to $33.0 million; the TTM value through Dec 2025 reached $33.0 million, down 26.88%, while the annual FY2025 figure was $33.0 million, 26.88% down from the prior year.
  • Total Current Liabilities reached $33.0 million in Q4 2025 per CCCC's latest filing, down from $35.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $55.0 million in Q1 2024 to a low of $30.3 million in Q3 2023.
  • Average Total Current Liabilities over 5 years is $43.9 million, with a median of $44.5 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: plummeted 33.13% in 2023, then soared 43.02% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $51.2 million in 2021, then fell by 13.07% to $44.5 million in 2022, then dropped by 4.0% to $42.8 million in 2023, then rose by 5.64% to $45.2 million in 2024, then decreased by 26.88% to $33.0 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Total Current Liabilities are $33.0 million (Q4 2025), $35.9 million (Q3 2025), and $44.5 million (Q2 2025).